Aim To observe the therapeutic effect and cadiovascular adverse reaction of rh-endostatin injection (YH-16,Endostar) combined with paclitaxel and cisplatin on advanced non-small-cell lung cancer(NSCLC). Methods Endostar combined with paclitaxel and cisplatin were administrated to 43 advanced non-small-cell lung cancer cases of stage Ⅲ-Ⅳ. Every course lasted 3 weeks,and all cases were evaluated after 2 courses at least; and safety was evaluated after one course. Results The objective response rate (ORR) was 48.79% (21/43) and disease control rate (DCR) was 81.4 % (35/43),1-year overall survival rate was 51.2%,median survival time was 12.2 months. The quality of life (QOL) were improved on 29 cases (67.44%),decreased on 6 cases (6/43). The occurrence rates of G3/4 toxicities were low,including neutropenia (11.63%,5/43),thrombocytopenia (6.98%,3/43),nausea/vomiting (4.65%,2/43). These toxicities were mainly related with the chemotherapy agents. Conclusion Endostar combined paclitaxel and cisplatin as the first line on advanced non-small-cell lung cancer is highly effective and safe. The QOL of patients with advanced lung cancer may be improved by endostar combined with the paclitaxel and cisplatin chemotherapy. It indicates that endostar has synergetic effects on some of cytotoxic agents or reverses tumor drug resistance such as paclitaxel and cisplatin. It is worthy of clinical generalization and further clinical observation.